(Boursier.com) — Pfizer the American pharmaceutical giant, announced on Monday the scheduled acquisition of the US laboratory Global Blood Therapeutics, a blood specialist, for $5.4 billion. The proposed acquisition will “drive growth” by bringing leading expertise, portfolio and pipeline in sickle cell disease to Pfizer, with potential peak combined global sales of more than $3 billion. Pfizer also discusses the potential “to meet all of the critical needs in the underserved sickle cell community.” The transaction is priced at $68.50 per share Global Blood Therapeutics in cash, representing a total enterprise value of approximately $5.4 billion. The boards of directors of the two groups have unanimously approved the transaction, which remains subject to the usual authorizations and conditions.
©2022 Boursier.com